ERBB2 and neoplasm: This study demonstrated that “dual-targeting” CAR T cells kill HER2+ tumor cells efficiently and proliferate in a manner that requires co-expression of MUC1 and HER2 by tumor cells, coupled with diminished damage to normal tissues expressing single antigen.